Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy

Kanke, Yasuyuki; Saito, Motonobu; Abe, Noriko; Saito, Katsuharu; Goto, Akiteru; Ohtake, Tohru; Murakami, Yoshinori; Kono, Koji

doi:10.3892/ol.2018.9727

Cited by 5 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, overexpression of CADM4 was efficient in suppressing the tumorigenicity of cancer cells [8,9,11]. Similar to these results, a decrease in or loss of expression of CADM4 in tumor cells was associated with aggressive clinicopathological phenotypes and poor prognosis, suggesting the potential of CADM4 as a tumor suppressor [10,[12][13][14][15][16][17][18].…”

Section: Introductionsupporting

confidence: 73%

Decreased Expression of Cell Adhesion Molecule 4 in Gastric Adenocarcinoma and Its Prognostic Implications

et al. 2022

View full text Add to dashboard Cite

Cell adhesion molecule 4 (CADM4) is a novel tumor suppressor candidate. The prognostic implications of CADM4 in gastric cancer have not been conclusively elucidated. Therefore, we evaluated the clinicopathological significance and prognostic value of CADM4 expression in a large series of patients with gastric adenocarcinoma. Immunohistochemical staining for CADM4 was performed on 534 gastric adenocarcinomas. We evaluated the associations between CADM4 expression and the clinicopathological and molecular characteristics of the adenocarcinomas. The prognostic effect of CADM4 expression was evaluated by survival analyses. Low CADM4 expression was significantly associated with young age (p = 0.046), aggressive histological type (p < 0.001), high pT category (p < 0.001), nodal metastasis (p < 0.001), high stage (p = 0.002), lymphovascular invasion (p = 0.001), and perineural invasion (p = 0.001). Low CADM4 expression was more frequently observed in tumors without human epidermal growth factor receptor 2 (HER2) amplification (p = 0.002). Low CADM4 expression was associated with worse overall survival (p = 0.007) and recurrence-free survival (p = 0.005) in the survival analyses. Low CADM4 expression was associated with aggressive clinicopathological features and poor clinical outcomes. CADM4 can act as a tumor suppressor in gastric adenocarcinoma and can be considered a prognostic biomarker.

show abstract

Section: Introductionsupporting

confidence: 73%

Decreased Expression of Cell Adhesion Molecule 4 in Gastric Adenocarcinoma and Its Prognostic Implications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The transcription factor GATA3 is overexpressed in lower grade breast tumors with a better prognosis, while its low levels are correlated with larger tumors [ 21 , 22 ]. Similarly, a lack of expression of the cell adhesion molecule CADM1 is associated with an advanced tumor stage, suggesting that inactivation of CADM1 promotes breast cancer development [ 23 , 24 ].…”

Section: Resultsmentioning

confidence: 99%

Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities

Kordias

Kostara

Papadaki

et al. 2022

Cells

View full text Add to dashboard Cite

The emergence of drug resistance in cancer poses the greatest hurdle for successful therapeutic results and is associated with most cancer deaths. In triple negative breast cancer (TNBC), due to the lack of specific therapeutic targets, systemic chemotherapy is at the forefront of treatments, but it only benefits a fraction of patients because of the development of resistance. Cancer cells may possess an innate resistance to chemotherapeutic agents or develop new mechanisms of acquired resistance after long-term drug exposure. Such mechanisms involve an interplay between genetic, epigenetic and metabolic alterations that enable cancer cells to evade therapy. In this work, we generated and characterized a chemoresistant TNBC cell line to be used for the investigation of mechanisms that drive resistance to paclitaxel. Transcriptomic analysis highlighted the important role of metabolic-associated pathways in the resistant cells, prompting us to employ 1H-NMR to explore the metabolome and lipidome of these cells. We identified and described herein numerous metabolites and lipids that were significantly altered in the resistant cells. Integrated analysis of our omics data revealed MSMO1, an intermediate enzyme of cholesterol biosynthesis, as a novel mediator of chemoresistance in TNBC. Overall, our data provide a critical insight into the metabolic adaptations that accompany acquired resistance in TNBC and pinpoint potential new targets.

show abstract

“…Motonobu et al found that CADM1 downregulation promoted advanced breast cancer progression and was strongly associated with tumor malignancy. 22 Deletion of CADM1 expression in bladder cancer was associated with adverse pathological factors, and overexpressing CADM1 in bladder cancer cell lines resulted in reduced cell proliferation and invasion rates. 23 Li et al found that CADM1 is a target of miR-486 in ovarian cancer cells, and this regulation could affect cell cycle progression and apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Effect of CADM1 on TPF-induced chemotherapy in laryngeal squamous cell carcinoma

Nie

Li²,

Tan³

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Objectives To explore the relationship between CADM1 expression and sensitivity to TPF-induced chemotherapy in laryngeal squamous cell carcinoma (LSCC) patients, then investigate its potential mechanisms. Methods Differential CADM1 expression was examined in chemotherapy-sensitive and chemotherapy-insensitive LSCC patient samples after TPF-induced chemotherapy using microarray analysis. Receiver operating characteristic (ROC) curve analysis and bioinformatics approaches were used to investigate the diagnostic value of CADM1. Small interfering RNAs (siRNAs) were used to knock down CADM1 expression in an LSCC cell line. Differential CADM1 expression was compared by qRT-PCR assays in 35 LSCC patients treated with chemotherapy, including 20 chemotherapy-sensitive and 15 chemotherapy-insensitive patients. Results Public database and primary patient data both suggest that CADM1 mRNA is expressed at lower levels in chemotherapy-insensitive LSCC samples, suggesting its potential usefulness as a biomarker. Knockdown of CADM1 with siRNAs led to decreased sensitivity of LSCC cells to TPF chemotherapy. Conclusions Upregulation of CADM1 expression can alter the sensitivity of LSCC tumors to TPF induction chemotherapy. CADM1 is a possible molecular marker and therapeutic target for induction chemotherapy in LSCC patients.

show abstract

Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy

Cited by 5 publications

References 30 publications

Decreased Expression of Cell Adhesion Molecule 4 in Gastric Adenocarcinoma and Its Prognostic Implications

Decreased Expression of Cell Adhesion Molecule 4 in Gastric Adenocarcinoma and Its Prognostic Implications

Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities

Effect of CADM1 on TPF-induced chemotherapy in laryngeal squamous cell carcinoma

Contact Info

Product

Resources

About